Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug could cut injection frequency for Diabetes-Related vision loss

NCT ID NCT07449936

Disease control Sponsor: EyePoint Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 7 times

Summary

This phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision over a year. The goal is to see if EYP-1901 can control DME with fewer injections than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EYP-1901 (a tyrosine kinase inhibitor) and aflibercept
What this could lead to
If successful, EYP-1901 could offer a longer-lasting treatment for diabetic macular edema, reducing the number of eye injections needed to control vision loss.
What could go wrong
This is a phase 3 trial, but results may not show EYP-1901 is as effective as aflibercept. Risks include eye inflammation, infection, or vision changes from the injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit. * Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 78 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1). * For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit. Exclusion Criteria: * BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic macular edema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystoid macular edema diabetes mellitus diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic macular edema Diabetic macular edema (DME) DME

Contacts and locations

Locations

  • Advance Medical Research Group, Inc

    Deerfield Beach, Florida, 33064, United States

  • Advanced Research LLC Sibia Eye Institute

    Boynton Beach, Florida, 33437, United States

  • Asheville Eye Associates - Regional Medical Park

    Asheville, North Carolina, 28803, United States

  • Augenklinik Universitaetsmedizin der Johannes Gutenberg-Univ.

    Mainz, Germany

  • Bnai Zion Medical Center

    Haifa, Israel

  • California Eye Specialists Medical Group, Inc.

    Redlands, California, 92373, United States

  • California Retina Consultants

    Bakersfield, California, 93309, United States

  • Cape Fear Retinal Associates, PC

    Wilmington, North Carolina, 28401, United States

  • Carmel Medical Center

    Haifa, Israel

  • Centrum Diagnostyki i Mikrochirurgii Oka -LENS Sp. z o. o

    Olsztyn, Poland

  • Centrum Medyczne UNO-MED

    Tarnów, Poland

  • Charleston Neuroscience Institute - Beaufort

    Beaufort, South Carolina, 29902, United States

  • Colorado Retina Associates

    Lakewood, Colorado, 80228, United States

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740, United States

  • Erie Retina Research

    Erie, Pennsylvania, 16507, United States

  • Eye Associates of Pinellas

    Pinellas Park, Florida, 33782, United States

  • Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica

    Banská Bystrica, Slovakia

  • Foundation for Vision Research

    Grand Rapids, Michigan, 49546, United States

  • Georgia Retina

    Marietta, Georgia, 30060, United States

  • Global Research Management, Inc.

    Glendale, California, 91204, United States

  • Haik Humble Eye Center

    West Monroe, Louisiana, 71291, United States

  • Johns Hopkins Medicine - The Johns Hopkins Hospital Campus - Wilmer Eye Institute

    Baltimore, Maryland, 21287, United States

  • Kaplan Medical Center

    Rehovot, Israel

  • Meir Medical Center Ophthalmology Department

    Kfar Saba, Israel

  • Midwest Eye Institute - Carmel

    Carmel, Indiana, 11220, United States

  • Mt. Olympus Medical Research

    Houston, Texas, 77479, United States

  • NJ Retina - Toms River

    Toms River, New Jersey, 08755, United States

  • NJRetina Care Center - Teaneck

    Teaneck, New Jersey, 07666, United States

  • Nemocnica Poprad

    Poprad, Slovakia

  • Nemocnica s poliklinikou Trebisov a.s.

    Trebišov, Slovakia

  • New England Retina Consultants

    Springfield, Massachusetts, 01107, United States

  • Northeast Wisconsin Retina Associates

    Appleton, Wisconsin, 54914, United States

  • Northern California Retina Vitreous Associates Medical Group INC.

    Mountain View, California, 94040, United States

  • OFTALMIKA Sp. z o.o

    Bydgoszcz, Poland

  • Oculomedica Sp. z o.o.

    Bydgoszcz, Poland

  • Oftalmocentrum Betliarska

    Bratislava, Slovakia

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Piedmont Retina Specialists, P.A. - Winston-Salem Office

    Winston-Salem, North Carolina, 27103, United States

  • Rabin Medical Center

    Petah Tikva, Israel

  • Rambam Health Care Campus (RHCC)

    Haifa, Israel

  • Red River Research Partners

    Plainfield, Illinois, 60586, United States

  • Retina Associates of Michigan

    Grand Blanc, Michigan, 48439, United States

  • Retina Associates of Utah

    Salt Lake City, Utah, 84107, United States

  • Retina Associates of Western New York

    Rochester, New York, 14620, United States

  • Retina Consultants of Carolina P.A

    Greenville, South Carolina, 29605, United States

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii, 96701, United States

  • Retina Consultants of San Diego

    Poway, California, 92064, United States

  • Retina Consultants of Southern Colorado

    Colorado Springs, Colorado, 80909, United States

  • Retina Consultants of Texas

    Katy, Texas, 77494, United States

  • Retina Consultants of Texas

    Schertz, Texas, 78154, United States

  • Retina Group of Washington

    Chevy Chase, Maryland, 20815, United States

  • Retina Research Institute of Texas Integrated Clinical Research

    Abilene, Texas, 79606, United States

  • Retina Specialists - Towson

    Towson, Maryland, 21204, United States

  • Retina Specialists of Tampa

    Wesley Chapel, Florida, 33544, United States

  • Retina Vitreous Associates of Florida - Saint Petersburg

    St. Petersburg, Florida, 33711, United States

  • Retinal Consultants Medical Group

    Sacramento, California, 95841, United States

  • Retinal Consultants Medical Group - Parkcenter Drive

    Sacramento, California, 95825, United States

  • Salt Lake Retina

    West Jordan, Utah, 84088, United States

  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie

    Lublin, Poland

  • Shamir Medical Center Ophthalmology Out Patient Clinic

    Be’er Ya‘aqov, Israel

  • Sierra Eye Associates

    Reno, Nevada, 89502, United States

  • Southern Vitreoretinal Associates

    Tallahassee, Florida, 32308, United States

  • Tennessee Retina

    Nashville, Tennessee, 37203, United States

  • Texas Retina Associates

    Dallas, Texas, 75231, United States

  • Texas Retina Associates

    Plano, Texas, 75075, United States

  • The Retina Partners

    Encino, California, 91436, United States

  • The Tel-Aviv Sourasky Medical Centre

    Tel Aviv, Israel

  • Tulsa Retina Consultant

    Tulsa, Oklahoma, 74114, United States

  • Tyler Retina Consultants

    Tyler, Texas, 75703, United States

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • VRCNY/Long Island Vitreoretinal Consultants

    Westbury, New York, 11590, United States

  • Virginia Retina Center

    Warrenton, Virginia, 20186, United States

  • Warszawski Szpital Okulistyczny

    Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.